In-Depth Insights into the Anaphylaxis Market: Growth, Trends, and Opportunities for 2025-2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What Are the Projected Expansion Rates of the Anaphylaxis Market for the Next Decade?
In recent times, the anaphylaxis market has experienced substantial growth. The market is projected to expand from $3.24 billion in 2024 to $3.51 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.4%. The surge in the market during the historic period is linked to rising incidences of food allergies, heightened awareness about anaphylaxis, development in healthcare infrastructure, improved diagnosis and management strategies, and the growing accessibility of epinephrine auto-injectors.
Expectations are high for substantial growth in the anaphylaxis market in the coming years. The market is anticipated to reach $4.81 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.2%. This expansion in the forecast period is due to factors such as urbanization and changes in lifestyle, an increased number of anaphylaxis cases, higher disposable incomes in developing markets, government support for allergy research, and innovations in emergency treatment delivery systems. The forecast period is set to witness a rise in the demand for injectable auto-injectors, digital health solutions in anaphylaxis management, focus on product affordability, increase in preventative treatments and vaccines, as well as high use of biologics for allergy treatment.
What Drivers Are Shaping the Growth of the Anaphylaxis Market?
The growth of the anaphylaxis market is anticipated to be driven by the increasing incidence of food allergies. Immune system reactions to specific foods manifest as food allergies, with effects varying from mild to severe, including the life-threatening condition of anaphylaxis. Factors like evolving dietary patterns, environmental effects and enhanced awareness and diagnostic processes contribute to the growing occurrence of food allergies. Anaphylaxis treatments offer essential, life-saving interventions to individuals with food allergies. These treatments quickly reverse severe allergic reactions, mitigate symptoms such as swelling, breathing difficulties, and low blood pressure, secure instant stabilization and prevent potential fatal results, thus equipping individuals for prompt response in future allergic situations. For example, as per the World Health Organization (WHO), a UN organization based in Switzerland, around 220 million individuals worldwide were affected by food allergies as of September 2024. A food item can have numerous allergens, and a single individual can be allergic to different kinds of food. Additionally, the Patterns and Prevalence of Adult Food Allergy (PAFA) report by the Food Standards Agency (FSA), a UK-based non-ministerial agency, revealed in May 2024 that over 30% of adults had adverse reactions to food and clinical reviews confirmed food allergies in roughly 6% of UK adults, translating to about 2.4 million individuals. Thus, the growing incidence of food allergies is stimulating the expansion of the anaphylaxis market.
Request Your Free Anaphylaxis Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21096&type=smp
Which Companies Are Redefining the Future of the Anaphylaxis Market?
Major companies operating in the anaphylaxis market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline Plc, F. Hoffman-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Perrigo Company plc, Dr Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals Inc., Mylan N.V., ALK-Abelló, Stallergenes Greer, Allergy Therapeutics
What Trends Are Poised to Drive the Future Success of the Anaphylaxis Market?
Prominent players in the anaphylaxis market are concentrating their efforts on producing state-of-the-art epinephrine nasal sprays that promise a quicker and more effective response in emergency situations. This medical device administers epinephrine, or adrenaline, via the nasal passage to combat severe allergic reactions, including anaphylaxis. To exemplify, in August 2024, US-based biotech firm ARS Pharmaceuticals received approval from the US Food and Drug Administration for its product Neffy (an epinephrine nasal spray), making it the first and only non-needle treatment for type I allergic responses, inclusive of anaphylaxis. This ground-breaking nasal spray offers a non-invasive substitute to conventional epinephrine autoinjectors, presenting a potentially more approachable alternative for emergency care. Neffy is designed to enhance patient adherence by removing the requirement for needles, and ensures rapid delivery of potentially life-saving epinephrine in cases of severe allergic reactions.
Pre-order Your Report for Quick and Easy Delivery!
https://www.thebusinessresearchcompany.com/report/anaphylaxis-global-market-report
How Are Key Segments Defining the Competitive Landscape of the Anaphylaxis Market?
The anaphylaxis market covered in this report is segmented –
1) By Drug Class: Epinephrine, Steroids, Antihistamines, Beta-antagonists, Other Drug Class
2) By Route Of Administration: Parenteral, Oral, Other Routes Of Administration
3) By Application: Food Allergy, Pollen Allergy, Dust Mites Allergy, Other Applications
Subsegments:
1) By Epinephrine: Auto-injectors, Prefilled Syringes, Vials
2) By Steroids: Corticosteroids, Glucocorticoids, Mineralocorticoids
3) By Antihistamines: H1-receptor Antagonists, H2-receptor Antagonists
4) By Beta-antagonists: Selective Beta-blockers, Non-selective Beta-blockers
5) By Other Drug Class: Leukotriene Receptor Antagonists, Mast Cell Stabilizers
What Are the Leading Regions in the Anaphylaxis Market Expansion?
North America was the largest region in the anaphylaxis market in 2024. The regions covered in the anaphylaxis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Core Features That Define the Anaphylaxis Market?
Anaphylaxis is a severe, life-threatening allergic reaction that occurs rapidly, often resulting in difficulty breathing, swelling, and a drop in blood pressure, requiring immediate medical intervention. Management of anaphylaxis involves prompt administration of epinephrine, followed by monitoring in a healthcare setting to stabilize the patient and prevent further complications.
Browse Through More Similar Reports By The Business Research Company:
Vaccine Adjuvants Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/vaccine-adjuvants-global-market-report
Enzyme Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report
Focal Segmental Glomerulosclerosis Drugs Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
